CINCINNATI--(BUSINESS WIRE)--CinDome Pharma, a CinRx portfolio company, will present a poster at the 2023 Digestive Disease Week (DDW) Conference, held May 6 th – 9 th in Chicago, Illinois. The poster ...

SPY001 is a novel, half-life extended α4β7 antibody in development for the treatment of Inflammatory Bowel Disease (IBD) SPY001 pharmacokinetic (PK) data up to eight months continues to support a ...

Poster presentation scheduled for Tuesday, May 5th at 12:30 PM CDT Denver, CO, April 16, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage ...

What goes on inside your digestive system? Your body needs food to stay healthy, but how does it turn food into the nutrients you need? Dive inside the Digestive System and find out.

IBSRELA (tenapanor) is a locally acting inhibitor of the sodium/hydrogen exchanger 3 (NHE3), an antiporter expressed on the apical surface of the small intestine and colon primarily responsible for ...

Ardelyx, Inc. (Nasdaq: ARDX), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs, today ...

An introduction to the amazing functions of the human body's digestive system. An introduction to the amazing functions of the human body's digestive system. Our continued survival as individuals and ...

Digestive enzymes are found in the digestive system, including the mouth, stomach, and small intestine. They help you break down food and absorb nutrients. Sometimes, the body cannot make enough ...

The digestive system is a group of organs that work together to change the food you eat into the energy and nutrients your body needs. After you consume food and liquids, the digestive system breaks ...

Common digestive issues include constipation, diarrhea, bloating, and the feeling of an unfinished bowel movement. These are often symptoms of different digestive disorders, such as irritable bowel ...

Palisade Bio is now advancing towards a Phase 2 clinical study in UC designed to evaluate clinical remission, response and pharmacodynamic biomarkers over 12 weeks, with an extension phase assessing ...